You Position: Home > Paper

Clinical effects of docetaxel combined with compound tegafur capsule in the treatment of 38 patients with anthracycline-refractory recurrent metastatic breast cancer

( views:604, downloads:9 )
Author:
No author available
Journal Title:
Cancer Research and Clinic
Issue:
12
DOI:
10.3760/cma.j.issn.1006-9801.2011.12.004
Key Word:
乳腺肿瘤;抗肿瘤联合化疗方案;多西紫杉醇;替吉奥;Breast neoplasms;Antineoplastic combined chemotherapy protocl;Docetaxel;Compound tegafur capsule

Abstract: Objective To investigate the efficacy and toxicity of docetaxel combined with compound tegafur capsule (S-1) on anthracycline-refractory recurrent metastatic breast cancer (ARMBC).Methods Thirty-eight ARMBC patients were given intravenous 70 mg/m2 docetaxel at day 1,and oral 60 mg/m2 S-1twice every day at day 1 to 14.Every 3 weeks was one cycle and each patient received at least two cycles.Results After treatment,among these 38 patients,there was 2 complete response (CR) (5.3 %),20 partial response (PR) (52.6 %),10 stable disease (SD) (26.3 %),and 6 progressive disease (PD) (15.8 %).Overall objective response rate was 57.9 % (95 % confidence intervaal: 42.6 %-74.2 %) while clinical benefit response rate was 73.7 % (95% confidence interval: 58.4 %-89.1%).The median time to progression (TTP) was 7.8 months (95 % confidence interval: 6.7-8.9 months),and median overall survival time (OS) was 15.7 months (95 % confidence interval: 12.9-18.8 months).The main toxic reaction was myelosuppression,and grade Ⅲ and Ⅳ adverse events including leucopenia occurred in 21.1% of all cases.Most common grade Ⅰ and Ⅱ adverse events,such as hand-foot syndrome,nausea,vomiting,diarrhea,liver dysfunction,and oral mucositis,were tolerable.Conclusion Good clinical efficacy is achieved in the therapy of metastatic breast cancer with docetaxel and S-1 combination regimen and toxic reaction is tolerable.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn